The paper "Economic Burden of Asthma Disease in Queensland" is a wonderful example of a research proposal on macro and microeconomics. Asthma is a disease that has a high economic burden not just in Australia but also globally. It affects the sufferers, their families as well as the community in general. This research paper will examine the economic burden of asthma at various levels and the difference between the severity and control of asthma. In society, poor control of asthma has led to an economic burden. In Queensland, the demand for acute or emergency health care services is exceedingly high because of uncontrolled asthma, which is very expensive as compared to the planned treatment.
Asthma has both direct and indirect economic costs and the latter is associated with poorly controlled asthma which results in reduced productivity and performance as a result of an increased rate of absenteeism. Essentially, when asthma is poorly controlled it results in significant economic burden, related to high costs not just to the patient but also to the community at large. As will be demonstrated in this piece, the economic costs related to asthma are one of the highest amongst the chronic diseases mainly because of the increased use of health care services related to this condition.
The asthma-related cost consists of both disease costs burden and economic costs. The economic costs components include productivity losses, health system costs, formal care, government programs, and deadweight efficiency losses. The main objective of this study will be to determine the economic burden of asthma disease in Queensland (QLD). Background/IntroductionAsthma, as mentioned by Bahadori et al. (2009), is a lungs’ inflammatory disorder that affects all people regardless of their age and it is a major contributor to mortality as well as morbidity globally.
The condition’ s prevalence is increasing not just amongst the adults but also in children. According to Nunes, Pereira, and Morais-Almeida (2017), Asthma disease-related costs can be grouped into intangible, indirect, and direct costs. The intangible costs are associated with unquantifiable losses, like reduced life quality, physical activity limitation, increases in suffering or pain, as well as job changes.
ACAM. (2005). Health care expenditure and the burden of disease due to asthma in Australia. Australian Centre for Asthma Monitoring. Canberra: AIHW.
Bahadori, K., Doyle-Waters, M. M., Marra, C., Lynd, L., Alasaly, K., Swiston, J., & FitzGerald, J. M. (2009). Economic burden of asthma: a systematic review. BMC Pulmonary Medicine, 9(24), 1-16.
Chastek, B., Korrer, S., Nagar, S. P., Albers, F., Yancey, S., Ortega, H., . . . Dalal, A. A. (2016). Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting. Journal of Managed Care & Specialty Pharmacy, 22(7), 848-861.
Deloitte Australia. (2015). The Hidden Cost of Asthma. Barton ACT: Deloitte Access Economics Pty Ltd.
Nunes, C., Pereira, A. M., & Morais-Almeida, M. (2017). Asthma costs and social impact. Asthma Research and Practice, 3(1), 1-11.
Rysiak, E., Kuczynski, A., Zaręba, I., Mroz, R. J., & Pałka, J. (2016). Evaluation of the treatment costs of asthma exacerbations in outpatients. Acta Poloniae Pharmaceutica ñ Drug Research, 73(1), 239ñ245.
Zannetos, S., Zachariadou, T., Zachariades, A., Georgiou, A., & Talias, M. A. (2017). The economic burden of adult asthma in Cyprus; a prevalence-based cost of illness study. BMC Public Health, 17, 1-9.